AGENDIA AT THE 2022 ASCO ANNUAL CONFERENCE
Agendia will present new data from ongoing clinical research evaluating the combination of MammaPrint and BluePrint genomic tests. The Data will highlight Agendia’s clinical focus on whole transcriptome analysis as well as breast cancer care for underserved populations, in addition to several sub-studies derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study. Two abstracts selected by ASCO for oral discussion will feature an investigation of the ImPrint genomic test, currently for research use only, from the I-SPY trial series and an analysis from FLEX of hormone receptor-positive breast cancer in Black women classified by BluePrint.
We invite you to meet our team via live chat. We can discuss genomic testing in the pre-operative setting, or answer any questions you might have.